KedRAB Supply -- There is a "firm commitment to minimum orders for 2025 through 2027" with distribution agreement extended to ...

Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; ...

Millennial Potash Corp. (TSXV: MLP) (OTCQB: MLPNF) (FSE: X0D) ("MLP", "Millennial" or the "Company") commends the recent announcement that potash has officially been added to 2025 List of Critical ...

Revenue -- Reported at $3.7 million for the three months ended September 30, 2025, up from $2.3 million in the same period in 2024; the increase was due to a $1.5 million rise in license revenues, ...

Gold price (XAU/USD) trades 2% higher to near $4,080 during the European trading session on Monday. The yellow metal ...

Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable ...

U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world evidence, expected to accelerate with seamless prescribing ...

Vir Biotechnology, Inc. today announced that Week 48 endpoint analysis from the Company's Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants receiving a monthly ...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the ...

Aerodrome Finance (AERO), and Pump.fun (PUMP) champion the strong cryptocurrency market recovery at press time on Monday as ...

The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in patients with Sézary syndrome (SS) and Mycosis fungoides (MF), who failed at least one prior line ...